Back to Search
Start Over
Crizotinib in ROS1 and MET Deregulated NSCLC—Response
- Source :
- Clinical Cancer Research. 26:1775-1775
- Publication Year :
- 2020
- Publisher :
- American Association for Cancer Research (AACR), 2020.
-
Abstract
- We thank the authors for their interest in our study and for their comments. Wiesweg and colleagues correctly reported that the minor allele frequency of both p.T1010I and p.R988C MET variants is close to 1% in the European population, but these mutations were described also as somatic (T1010I
- Subjects :
- 0301 basic medicine
Cancer Research
Lung Neoplasms
Somatic cell
03 medical and health sciences
0302 clinical medicine
Crizotinib
Proto-Oncogene Proteins
Protein-Tyrosine Kinases
Carcinoma
ROS1
Humans
Medicine
Prospective Studies
Non-Small-Cell Lung
Prospective cohort study
Protein Kinase Inhibitors
business.industry
European population
medicine.disease
Minor allele frequency
030104 developmental biology
Oncology
030220 oncology & carcinogenesis
Carcinoma, Non-Small-Cell Lung
Cancer research
business
medicine.drug
Subjects
Details
- ISSN :
- 15573265 and 10780432
- Volume :
- 26
- Database :
- OpenAIRE
- Journal :
- Clinical Cancer Research
- Accession number :
- edsair.doi.dedup.....bae76e8f0ba5983bf66be17504937816
- Full Text :
- https://doi.org/10.1158/1078-0432.ccr-20-0026